Thus, we investigated the role of FTO in erlotinib and osimertinib resistance in EGFR-mutated and wild-type NSCLC cells, and we hypothesized that modulating FTO could be key to overcoming EGFR-TKI resistance in these resistant cell lines. This evidence concerns the gene FTO and non-small cell lung carcinoma.